Johnson and Johnson’s Tremfya (guselkumab) was superior to its Stelara (ustekinumab) medication in all endoscopic endpoints in a Phase II/III Crohn’s disease (CD) trial.
Recommended Buyer's Guides
Data from the Phase II/III Galaxi trial (NCT03466411) showed that Tremfya was superior in endoscopic response, endoscopic remission, clinical remission and endoscopic response, and deep remission.
Go deeper with GlobalData
The Phase II/III trial pitted Tremfya against J&J’s Stelara in adult patients with moderately to severely active CD.
Both maintenance doses, 100mg every eight weeks and 200mg every four weeks, met the composite co-primary endpoints compared to placebo in each study. When pitted against Stelaraboth doses demonstrated statistically significant and clinically meaningful differences on all endoscopic endpoints at 48 weeks.
The safety profile observed in the Galaxi programme is consistent with previous trials in approved indications.
This month, Johnson & Johnson Innovative Medicine (formerly Janssen Pharmaceuticals), submitted applications to the European Medicines Agency (EMA) to expand the marketing authorisation application for Tremfya for adult patients with moderately to severely active ulcerative colitis (UC) and moderately to severely active CD.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataJohnson & Johnson took the lead with the regulatory application for Tremfya for the treatment of adults with moderately to severely active UC in other countries or regions including the US.
On 21 May, Johnson & Johnson announced that Tremfya met the primary endpoints in a Phase III UC trial.
The Galaxi programme included one Phase II dose-ranging study (Galaxi 1) and two confirmatory Phase III studies (Galaxi 2 and 3).
CD landscape
Crohn’s disease is a type of inflammatory bowel disease characterised by chronic inflammation of the gastrointestinal (GI) tract.
Crohn’s disease can appear at any age, but it is most often diagnosed in adults in their 20s and 30s. Approximately 30% of people with Crohn’s disease develop symptoms before the age of 20.
A GlobalData report estimates CD drug sales across the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan, and Canada) will increase from $9.5bn to $15bn by 2032. This growth is predicted to be driven by the approval and launches of 15 pipeline, generic, and biosimilar therapies.
GlobalData is the parent company of the Clinical Trials Arena.
